BGNE Stock Recent News
BGNE LATEST HEADLINES
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average.
BeiGene's shares are up more than 8% this year. The company has more than 60 clinical programs.
BeiGene aims to tap the area's life sciences talent pool.
BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice.
The year 2022 proved to be the worst calendar year for the S&P 500 since 2008.
The Chinese pharmaceutical stock is experiencing a comeback.